Tirzepatide and the Pancreas: Separating Concern from Evidence

The misconception worth correcting first: pancreatitis isn't common, but it isn't a myth either

A lot of people arrive with one of two misreadings. Either they've heard that tirzepatide destroys the pancreas and they're terrified, or they've been told the pancreatitis link is scare-mongering with no real basis. Neither is accurate.

The pancreas produces enzymes that digest food and hormones (including insulin) that regulate blood sugar. GLP-1 receptor agonists, and tirzepatide as a dual GIP/GLP-1 agonist, influence several of these pathways. In large clinical trials, acute pancreatitis events were reported at low rates, but they did occur. On 29 January 2026, the MHRA published a Drug Safety Update specifically flagging acute pancreatitis as a serious, known risk across GLP-1 medicines. That is a regulator doing its job properly — not evidence of a widespread problem, but a clear signal that the risk is real enough to monitor.

The clinical programme for tirzepatide involved thousands of adults across the SURMOUNT trials. Pancreatitis was not the defining safety signal, and it did not alter the medicine's benefit-risk profile for people without the relevant risk factors. The specific risk factors and what the trial data found are covered in more detail in a dedicated page if you want to go deeper.

Short version: uncommon, but real, and worth knowing about.

When stomach pain needs urgent medical attention

This is the section that matters most. The reason pancreatitis gets particular attention is that it can escalate quickly if ignored, and its early symptom (stomach pain) overlaps with the garden-variety nausea and discomfort that many people experience in the first weeks of tirzepatide as their gut adjusts.

The difference is character and duration. Ordinary GI side effects on tirzepatide tend to be nausea, loose stools, burping, or a general feeling of fullness, generally peaking in the first day or two after an injection and gradually settling. If you want to understand more about how tirzepatide and diarrhea are connected and why loose stools happen, that is covered separately. Pancreatitis pain is different: severe, persistent, often located in the upper abdomen, and frequently spreading through to the back. It typically doesn't ease by itself over an hour or two, and it may be accompanied by vomiting that doesn't bring relief.

If you experience that kind of pain (severe, doesn't pass, moves to your back) get medical help the same day. Call 111 or, if the pain is acute and worsening, 999 or A&E. Do not sit it out hoping it's just the usual settling-in discomfort. The NHS tirzepatide medicines page sets out these warning signs in the same terms.

Other symptoms that need prompt attention include severe vomiting that is stopping you keeping fluids down, signs of an allergic reaction, or yellowing of the skin or eyes, which may point to a gallbladder issue, another condition with a known association with GLP-1 medicines. These are distinct from the routine side-effect profile and are covered more fully on our Mounjaro side effects page.

Who should be especially cautious about tirzepatide and the pancreas

Certain medical histories mean a prescriber will want to weigh the risk particularly carefully. A personal history of pancreatitis (acute or chronic) is one of the most important things to disclose, and if you want a fuller picture of how Mounjaro affects the pancreas and what the evidence actually shows, we cover that in detail elsewhere. So is a history of gallstones or gallbladder disease, since gallstones are an established trigger for pancreatitis and GLP-1 medicines can increase gallbladder-related events. Heavy alcohol use is another factor, as it is an independent risk for pancreatic inflammation.

Medullary thyroid carcinoma and Multiple Endocrine Neoplasia type 2 (MEN2) are contraindications to tirzepatide, and while they relate to the thyroid rather than the pancreas directly, they belong to the same conversation about endocrine history that a prescriber will have with you.

This is exactly the kind of history that nume's (that nume's) prescribers go through in the consultation. There is a reason the process involves a real clinician rather than a checkbox form. If you'd like to explore how a consultation works, our FAQs walk through what to expect.

A practical note on routine: keeping your pen in the fridge door where you'll see it regularly also makes it easy to keep a mental note of the day you inject, which matters when you're tracking whether any stomach discomfort appeared within a day or two of a dose. Pattern awareness is a useful habit.

Reporting and how to use the Yellow Card scheme

If you experience a side effect you think is linked to tirzepatide (whether or not it seems serious) you can report it through the MHRA's Yellow Card scheme. This applies to any suspected adverse reaction: the data collected through Yellow Card helps the MHRA track real-world safety patterns and, where needed, update guidance. You don't need a confirmed diagnosis to report; suspicion is enough. It is also worth knowing that tirzepatide and mood changes are among the experiences people report, and those too are worth logging if you notice them.

The same scheme lets you flag suspect medicines or sellers if you have concerns about a product's authenticity. For people using a GPhC-registered pharmacy like nume (like nume) medicines come through the licensed UK supply chain, but for anyone who obtained tirzepatide elsewhere, Yellow Card is the right place to raise concerns.

Our prescribers discuss the full side-effect profile (including the pancreas question) as part of every consultation. If you're weighing up whether tirzepatide is appropriate for your circumstances, start your free consultation and a GPhC-registered prescriber will review your history the same day. You can also read more about how we approach clinical safety on our about page.